Market research
LNSR LENSAR Inc
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 107M
- P/E ratio
- 43.4
- Analyst target
- 11.5
- Dividend yield
- Not available
- Beta
- 0.88
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Medical Devices
- ISIN
- US52634L1089
- Market cap
- 107M
- P/E ratio
- 43.4
- Analyst target
- 11.5
- Dividend yield
- Not available
- Beta
- 0.88
About
About LENSAR Inc
LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing laser systems for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism in the United System, Europe, Asia, South Korea, and internationally. The company offers the LENSAR Laser System, which incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes by providing imaging, procedure planning, design, and precision. It also provides ALLY Robotic Cataract Laser System, a compact cataract treatment system that is designed to allow surgeons to perform sterile laser-assisted cataract surgery in a single operating room. LENSAR, Inc. was incorporated in 2004 and is headquartered in Orlando, Florida.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the LNSR discussion.
5 years, 4 months ago
From a valuation standpoint, the stock is 99.9% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 1.3.
Based on the above factors, LENSAR, Inc gets an overall score of 1/5.